Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Short Interest Up 572.7% in September

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw a significant increase in short interest in the month of September. As of September 30th, there was short interest totaling 74,000 shares, an increase of 572.7% from the September 15th total of 11,000 shares. Based on an average daily volume of 51,600 shares, the short-interest ratio is currently 1.4 days. Based on an average daily volume of 51,600 shares, the short-interest ratio is currently 1.4 days.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Wednesday, October 8th. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a report on Friday, September 19th. Finally, Leerink Partners set a $14.00 price objective on shares of Nanobiotix in a report on Thursday, September 18th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Nanobiotix currently has an average rating of “Hold” and a consensus price target of $11.00.

Nanobiotix Stock Performance

Shares of NBTX opened at $25.60 on Friday. Nanobiotix has a one year low of $2.76 and a one year high of $30.35. The company has a 50-day simple moving average of $14.16 and a two-hundred day simple moving average of $7.84.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.